826 abstracts found.



Results filter

Polycomb-mediated regulation of the INK4/ARF tumour suppressor locus

Year:

Session type:

Emma Anderton (1),Marc Rodriguez-Niedenfuhr (1),Goedele Maertens (1),Selma El Messaoudi-Aubert (1),Tomas Racek (1),Julie Stock (1),Gordon Peters (1)
Cancer Research UK London Research Institute, London, United Kingdom (1)

Fbw7 regulates intestinal cell lineage commitment and is a haploinsufficient suppressor of intestinal tumourigenesis

Year:

Session type:

Rocio Sancho (1),Anett Jandke (1),Hayley Davis (2),Markus Diefenbacher (1),Ian Tomlinson (2),Axel Behrens (1)
Cancer Research UK - London Research Institute, London, United Kingdom (1),University of Oxford, Oxford, United Kingdom (2)

Results of ICON7: a phase III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian (EOC), primary peritoneal (PPC) or fallopian tube cancer (FTC). Medical Research Council Cancer Trials Unit, presented on behalf of the GCIG ICON7 collaborators

Year:

Session type:

Jonathan Ledermann (2), Charlie Gourley (3), Sharadah Essapen (4), Gordon Rustin (5), Fiona Collinson (1), Sheryl Sim (1), Faisal Al-Terkait (1), Clare Griffin (6)
UCL Cancer Institute and Cancer Research UK and UCL Cancer Trials Centre, London, UK (2), University of Edinburgh Cancer Research Centre and Western General Hospital, UK (3), Royal Surrey County Hospital, Guildford, UK (4), Mount Vernon Hospital, Northwood, UK (5), Medical Research Council Cancer Trials Unit, London, UK (6)

Results of BC2001: A 2×2 phase III randomised trial of synchronous chemo-radiotherapy (CRT) compared to radiotherapy (RT) alone and standard (sRT) versus reduced high-dose volume RT (rvRT) in muscle invasive bladder cancer (MIBC) (CRUK/01/004

Year:

Session type:

Syed Hussain (1), Emma Hall (2), Peter Jenkins (3), Jean Tremlett (4), Christine Rawlings (5), Malcolm Crundwell (6), Rebecca Lewis (2), Carey Hendron (1), Rachel Waters (2), Robert Huddart (2)
The Institute of Cancer Research, Sutton, UK (2), Cheltenham General Hospital, UK (3), Brighton and Sussex University Hospitals NHS Trust, UK (4), South Devon Healthcare NHS Foundation Trust, Torbay, UK (5), Royal Devon and Exeter Hospital, UK (6)

The MRC Myeloma IX Trial: beneficial effects of thalidomide and zoledronic acid for newly diagnosed myeloma patients of all ages

Year:

Session type:

Walter Gregory (1), Faith Davies (2), Kim Cocks (1), Sue Bell (1), Alex Szubert (1), Nuria NavarroCoy (1), Mark Drayson (3), Roger Owen (4), Gordon Coo (4), Fiona Ross (5), Graham Jackson (6), Sylvia Feyler (7), John Ashcroft (8), Gareth Morgan (2)
The Institute of Cancer Research, Royal Marsden Hospital, London, UK (2), University of Birmingham, UK (3), St James’s University Hospital, Leeds, UK (4), University of Southampton, UK (5), University of Newcastle, UK (6), Calderdale and Huddersfield NHS Trust, Huddersfield, UK (7), Mid Yorkshire Hospitals NHS Trust, Wakefield, UK (8)

Intergroup randomized controlled phase III trial of Androgen Deprivation Therapy (ADT) +/- Radiation Therapy (RT) in locally advanced prostate cancer (CaP) (NCIC-CTG, SWOG, MRC, INT: T94-0110; NCT00002633)

Year:

Session type:

Padraig R Warde (2), Matthew R Sydes (3), Keyue Ding (8), Mary K Gospodarowicz (2), Gregory P Swanson (4), Peter Kirkbride (5), Ed Kostashuk (6), John Hetherington (7), Andrea Hiltz (8), Karen Sanders (3), John Anderson (5), Jim Barber (1), Mahesh KB Parmar (3), Wendy Parulekar (8)
Princess Margaret Hospital and University of Toronto, Canada (2), MRC Clinical Trials Unit, London, UK (3), University of Texas Health Science Center, San Antonio, USA (4), Weston Park Hospital, Sheffield, UK (5), British Columbia Cancer Agency, Surrey, Canada (6), Castle Hill Hospital, Hull, UK (7), NCIC Clinical Trials Group, Kingston, Canada (8)

Page 83 of 83« First...25...83